Predicting QRS and PR interval prolongations in humans using nonclinical data

0044 English OPEN
Bergenholm, Linnéa;
  • Subject: RM

Risk of cardiac conduction slowing (QRS/PR interval prolongations in monitored electrocardiograms) is assessed in nonclinical studies, where the current AstraZeneca strategy involves ensuring high margins to in vitro effects and statistical tests to identify in vivo eff... View more
  • References (147)
    147 references, page 1 of 15

    5.2 Parameter estimates for selected QRS baseline models in dogs . . . .

    5.3 Relative likelihood of the PR baseline models in dogs . . . . . . . . .

    5.4 Parameter estimates for selected PR baseline models in dogs . . . .

    5.5 Summary of the acquired AZD1305 data . . . . . . . . . . . . . . . .

    5.6 Parameter estimates for the dog AZD1305 PK model . . . . . . . . .

    5.7 Tested dog AZD1305 QRS models . . . . . . . . . . . . . . . . . . .

    5.8 Parameter estimates for the dog AZD1305 QRS model . . . . . . . .

    5.9 Tested dog AZD1305 PR models . . . . . . . . . . . . . . . . . . . .

    5.10 Parameter estimates for the dog AZD1305 PR model . . . . . . . . .

    5.11 Parameter estimates for the human AZD1305 PK model . . . . . . .

  • Metrics
Share - Bookmark